Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical firm at the forefront of enhancing cancer therapy through its proprietary localized drug delivery systems, which significantly improve the effectiveness of immuno-oncology agents. The company is strategically addressing the complexities of tumor microenvironments with a robust pipeline of clinical programs aimed at advancing treatment options in oncology. With a commitment to expanding patient access to transformative therapies, TriSalus is well-positioned to drive meaningful change in cancer care, aligning with the growing demand for advanced, effective cancer treatments. The company’s initiatives underscore its potential to be a key player in the rapidly evolving oncology landscape, attracting interest from both investors and healthcare stakeholders.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$4.64
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 6, 2026 | $-0.15 | $-0.16 | Miss -6.7% | $-0.16 | $10.27M | $11.41M | +11.1% | 1D Pre-2.5% | On-Day+5.4% | 1D Post+15.2% |
Q ended Mar 31, 2026 Reported May 12, 2026 | $-0.16 | $0.02 | Beat +112.5% | — | $10.44M | $8.9M | -14.8% | 1D Pre+2.5% | On-Day+0.4% | 1D Post-41.4% |
Q ended Dec 31, 2025 Reported Mar 5, 2026 | $-0.13 | $-0.05 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| Beat +61.5% |
| — |
| $13.2M |
| $13.21M |
| +0.1% |
| 1D Pre+1.2% |
| On-Day-4.6% |
| 1D Post-6.4% |
Q ended Sep 30, 2025 Reported Nov 13, 2025 | $-0.16 | $-0.87 | Miss -443.8% | — | $11.76M | $11.57M | -1.6% | 1D Pre+1.8% | On-Day-0.7% | 1D Post+3.9% |